Abstract
Sustained drug delivery providing continuous dopaminergic stimulation is thought to prevent or delay the induction of motor complications (dyskinesia) in Parkinson’s disease, whereas pulsatile administration is supposed to promote them. This study investigated the inducibility of sensitization and abnormal involuntary movements (AIMs), comparing continuous and pulsatile administration of rotigotine with pulsatile administration of 3,4-dihydroxy-l-phenylalanine (l-DOPA) for reference. Rats were unilaterally lesioned with 6 hydroxydopamine (6-OHDA). For pulsatile administration, l-DOPA-methylester (10 mg/kg l-DOPA i.p.) or rotigotine (1 mg/kg i.p.) were administered once or twice daily. For continuous administration, a slow release formulation of rotigotine was injected s.c. at a dose of 1 mg/kg every 48 h (experiment I) or every 24 h (experiment II). Pulsatile administration of rotigotine and l-DOPA caused contraversive rotations increasing progressively upon each successive treatment. AIMs started to occur after the second administration of l-DOPA but hardly after pulsatile rotigotine. Continuous rotigotine increased rotations, which reached a plateau after the second administration. No AIMs were observed under continuous administration. The continuous administration of rotigotine did not induce sensitization or AIMs, suggesting that continuous stimulation of dopaminergic receptors by rotigotine has no propensity to induce dyskinesia in this experimental model.
Similar content being viewed by others
References
Alam M, Mayerhofer A, Schmidt WJ (2004) The neurobehavioral changes induced by bilateral rotenone lesion in medial forebrain bundle of rats are reversed by l-DOPA. Behav Brain Res 151:117–124
Anagnostaras SG, Robinson TE (1996) Sensitization to the psychomotor stimulant effects of amphetamine: modulation by associative learning. Behav Neurosci 110:1397–1414
Arnt J, Hyttel J (1984) Differential inhibition by dopamine D-1 and D-2 antagonists of circling behaviour induced by dopamine agonists in rats with unilateral 6-hydroxydopamine lesions. Eur J Pharmacol 102:349–354
Bertaina-Anglade V, La Rochelle CD, Scheller DK (2006) Antidepressant properties of rotigotine in experimental models of depression. Eur J Pharmacol 548:106–114
Braak H, Del Tredici K, Bratzke H, Hamm-Clement J, Sandmann-Keil D, Rub U (2002) Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson’s disease (preclinical and clinical stages). J Neurol 249(Suppl 3):lll/1–lll/5
Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E (2003) Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24:197–211
Cenci MA, Lee CS, Bjorklund A (1998) l-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur J Neurosci 10:2694–2706
Cenci MA, Whishaw IQ, Schallert T (2002) Animal models of neurological deficits: how relevant is the rat? Nat Rev Neurosci 3:574–579
Chase TN (1998) Levodopa therapy: consequences of the nonphysiologic replacement of dopamine. Neurology 50:S17–S25
Chase TN, Engber TM, Mouradian MM (1994) Palliative and prophylactic benefits of continuously administered dopaminomimetics in Parkinson’s disease. Neurology 44(7 Suppl 6):S15–S18
Elshoff JP, Cawello W, Braun M, Horstmann R (2006) Stable plasma concentrations over 24 hours in patients with early-stage Parkinson’s disease after once-daily transdermal administration of rotigotine (Neupro®). Neurology 66:A293
Fahn S (2005) Does levodopa slow or hasten the rate of progression of Parkinson’s disease? J Neurol 252(Suppl 4):lV37–lV42
Gerlach M, Riederer P (1996) Animal models of Parkinson’s disease: an empirical comparison with the phenomenology of the disease in man. J Neural Transm 103:987–1041
Graybiel AM, Canales JJ, Capper-Loup C (2000) Levodopa-induced dyskinesias and dopamine-dependent stereotypies: a new hypothesis. TINS 23(10 Suppl):S71–S77
Grosset D (2006) The rotigotine transdermal patch may provide continuous dopaminergic stimulation in early-stage Parkinson’s disease. ACNR 6:32–34
Guldenpfennig WM, Poole KH, Sommerville KW, Boroojerdi B (2005) Safety, tolerability, and efficacy of continuous transdermal dopaminergic stimulation with rotigotine patch in early-stage idiopathic Parkinson disease. Clin Neuropharmacol 28:106–110
Herrera-Marschitz M, Ungerstedt U (1984) Evidence that apomorphine and pergolide induce rotation in rats by different actions on D1 and D2 receptor sites. Eur J Pharmacol 98:165–176
Hirsch EC, Hoglinger G, Rousselet E, Breidert T, Parain K, Feger J et al (2003) Animal models of Parkinson’s disease in rodents induced by toxins: an update. J Neural Transm Suppl 10:89–100
Jenner P (2004) Avoidance of dyskinesia: preclinical evidence for continuous dopaminergic stimulation. Neurology 62:S47–S55
Jenner P (2005) A novel dopamine agonist for the transdermal treatment of Parkinson’s disease. Neurology 65:S3–S5
Kehr J, Hu XJ, Goiny M, Scheller DK (2007) Continuous delivery of rotigotine decreases extracellular dopamine suggesting continuous receptor stimulation. J Neural Transm. 114:1027–1031
Lane EL, Cheetham SC, Jenner P (2006) Does contraversive circling in the 6-OHDA-lesioned rat indicate an ability to induce motor complications as well as therapeutic effects in Parkinson’s disease? Exp Neurol 197:284–290
Lee CS, Cenci MA, Schulzer M, Björklund A (2000) Embryonic ventral mesencephalic grafts improve levodopa-induced dyskinesia in a rat model of Parkinson’s disease. Brain 123(Pt 7):1365–1379
Lim E (2005) A walk through the management of Parkinson s disease. Ann Acad Med Singapore 34:188–195
Lundblad M, Andersson M, Winkler C, Kirik D, Wierup N, Cenci MA (2002) Pharmacological validation of behavioral measures of akinesia and dyskinesia in a rat model of Parkinson’s disease. Eur J Neurosci 15:120–132
Marin C, Rodriguez-Oroz MC, Obeso JA (2006) Motor complications in Parkinson’s disease and the clinical significance of rotational behavior in the rat: have we wasted our time? Exp Neurol 197:269–274
Metz GA, Tse A, Ballermann M, Smith LK, Fouad K (2005) The unilateral 6-OHDA rat model of Parkinson’s disease revisited: an electromyographic and behavioral analysis. Eur J Neurosci 22:735–744
Morelli M, Fenu S, Cozzolino A, Di Chiara G (1991) Positive and negative interactions in the behavioral expression of D1 and D2 receptor stimulation in a model of Parkinsonism: role of priming. Neuroscience 42:41–48
Obeso JA, Olanow CW, Nutt JG (2000) Levodopa motor complications in Parkinson’s disease. Trends Neurosci 23:S2–S7
Olanow CW, Obeso JA (2000) Preventing levodopa-induced dyskinesias. Ann Neurol 47:S167–S176
Paxinos G, Watson C (1986) The rat brain in stereotaxic coordinates, 2nd edn. Academic Press, San Diego, CA
Poewe W, Wenning G (2002) Levodopa in Parkinson’s disease: mechanisms of action and pathophysiology of late failure. In: Jankovic J, Tolosa E (eds) Parkinson’s disease and movement disorders. Lippincott Williams & Wilkins, Philadelphia, pp 104–115
Poewe W, Wenning GK (2000) Apomorphine: an underutilized therapy for Parkinson’s disease. Mov Disord 15:789–794
Reynolds NA, Wellington K, Easthope SE (2005) Rotigotine: in Parkinson’s disease. CNS Drugs 19:973–981
Scheller DKA (2006) Extended receptor profile of rotigotine, a non-ergolinic dopamine agonist being investigated in Parkinson’s Disease. Mov Disord 21:S80
Schwarting RK, Huston JP (1996) The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments. Prog Neurobiol 50:275–331
Siever L, Cohen R, Pert A (1981) Assessing pharmacologically induced dopamine receptor sensitivity changes with the Ungerstedt turning model. Psychopharmacology (Berl) 75:212–213
Srinivasan J, Schmidt WJ (2004) Treatment with alpha2-adrenoceptor antagonist, 2-methoxy idazoxan, protects 6-hydroxydopamine-induced Parkinsonian symptoms in rats: neurochemical and behavioral evidence. Behav Brain Res 154:353–363
Stocchi F, Olanow CW (2004) Continuous dopaminergic stimulation in early and advanced Parkinson’s disease. Neurology 62:S56–S63
Stocchi F, Vacca L, Ruggieri S, Olanow CW (2005) Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study. Arch Neurol 62:905–910
Ungerstedt U, Arbuthnott GW (1970) Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system. Brain Res 24:485–493
Acknowledgments
The investigators also wish to express their appreciation to U. Ruess and W. Jünemann, Department of Neuropharmacology, University Tuebingen, for careful handling of the animals and skilled performance of the investigations. The study was sponsored by SCHWARZ BIOSCIENCES, Alfred-Nobel Strasse 10, 40789, Monheim, Germany.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Schmidt, W.J., Lebsanft, H., Heindl, M. et al. Continuous versus pulsatile administration of rotigotine in 6-OHDA-lesioned rats: contralateral rotations and abnormal involuntary movements. J Neural Transm 115, 1385–1392 (2008). https://doi.org/10.1007/s00702-008-0102-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00702-008-0102-z